Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Brain Neoplasms × Vinorelbine × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 82 Carcinoma, Non-Small-Cell Lung 49 Lung Neoplasms 22 Hodgkin Disease 15 Recurrence 10 Lymphoma 10 Prostatic Neoplasms 7 Triple Negative Breast Neoplasms 6 Neoplasm Metastasis 6 Neoplasms 5 Lymphoma, Non-Hodgkin 4 Lymphoma, Large B-Cell, Diffuse 4 Adenocarcinoma of Lung 4 Sarcoma 3 Rhabdomyosarcoma 3 Mesothelioma, Malignant 3 Mesothelioma 3 Breast Neoplasms, Male 3 Ovarian Neoplasms 2 Neuroblastoma 2 Multiple Myeloma 2 Melanoma 2 Lymphoma, Large-Cell, Anaplastic 2 HER2-negative Breast Cancer 2 Fallopian Tube Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Advanced Breast Cancer 2 Waldenstrom Macroglobulinemia 1 Vinorelbine 1 Uterine Cervical Neoplasms 1

Interventions

Temozolomide 63 Bevacizumab 52 Radiotherapy 35 Radiosurgery 26 Carboplatin 21 pembrolizumab 15 Etoposide 15 Nivolumab 14 Irinotecan 14 Cisplatin 13 Carmustine 13 Magnetic Resonance Spectroscopy 12 Ipilimumab 12 Erlotinib Hydrochloride 12 Cyclophosphamide 12 Pemetrexed 11 Surgical Procedures, Operative 10 Topotecan 9 Lapatinib 9 Capecitabine 9 Thalidomide 8 Aminolevulinic Acid 8 Lomustine 7 Imatinib Mesylate 7 Gefitinib 7 Filgrastim 7 trametinib 6 osimertinib 6 encorafenib 6 cabozantinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03933982 2019-05-29

Pyrotinib

ChineseAMS

Phase 2 Unknown

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡